Imaginatik PLC Issue of Equity/Director's Dealing (1623V)

TIDMIMTK

RNS Number : 1623V

Imaginatik PLC

24 October 2014

Imaginatik Plc

("Imaginatik" or the "Company")

Issue of Equity/ Director's Dealing

Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offering a range of technology products and consultancy, is pleased to announce that Simon Charles, non-executive director, has subscribed for 1,339,285 ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares") at a price of 5.6 pence per Ordinary Share ("Subscription").

The Subscription is pursuant to an irrevocable commitment entered into by Mr Charles at the time of the placing of and subscription for new shares in the Company as announced on 25 April 2014. Subsequently, the Company has undergone a 1 for 80 share consolidation hence the price of the Subscription has been adjusted accordingly.

Accordingly, 1,339,285 new Ordinary Shares have been allotted and application has been made for the new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 29 October 2014. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 63,084,290. The Company does not hold any shares in treasury. Accordingly, the figure of 63,084,290 may be used by shareholders as the denominator for the calculations by which they will determine their interest in the Company under the FCA's Disclosure and Transparency Rules.

Following the Subscription and Admission, Mr Charles will hold 2,083,182 Ordinary Shares, representing 3.3 per cent. of the enlarged share capital.

For further information please contact:

Imaginatik plc

Tel: 01329 243243

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

finnCap

Tel: 0207 220 0500

Charlotte Stranner/ Victoria Bates

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Forde / Hilary Millar

About Imaginatik

Imaginatik(R) is the world's first full-service innovation provider. We have 16 years of experience building innovation into a sustainable competence at some of the world's largest and most respected companies. Through a mix of consulting and advisory, hands-on innovation projects and program management, and our award-winning enterprise software platform, we help clients develop innovation capability into a permanent competitive advantage. Imaginatik is the trusted partner of leading organisations including Blue Cross Blue Shield, CSC, Cargill, The World Bank, Mayo Clinic, The Chubb Group of Insurance Companies, HCA, Dow Chemical and Goodyear.

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Fareham, UK. For more information visit www.imaginatik.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEPGGMWUUPCGCW

Abal (LSE:ABAL)
Historical Stock Chart
From Jun 2024 to Jul 2024